Preventive measures and uptake of vaccines after the emergence of Mpox in the U.S. in August 2022 rapidly halted the outbreak and the official end to the Mpox emergency just months later, in January 2023.
Good news. But there's a data reality check: JYNNEOS vaccine coverage remains highly variable across jurisdictions. States and cities with particularly highly vaccination rates among high risk persons (for the initial of the two-dose regimen) include the District of Columbia, New York City and New York State, Illinois, Oregon, Massachusetts, and Oregon.
However, across-the-board, there is low uptake of the second dose, which is necessary to provide more robust protection. According to CDC, as of November 2023, "although approximately 1.2 million vaccine doses have been administered, only 23% of the population at risk has been fully vaccinated nationally."
See HRSA's Mpox Information webpage.